Curated News
By: NewsRamp Editorial Staff
July 16, 2025
NanoViricides Advances NV-387 Against MPox Following WHO Alert
TLDR
- NanoViricides, Inc. (NYSE American: NNVC) is advancing NV-387 into Phase II trials, positioning it to capture multi-billion-dollar markets including bioterrorism stockpiles.
- NV-387, NanoViricides' broad-spectrum antiviral, mimics human cells to block viral entry, potentially avoiding resistance, with Phase I trials confirming its safety profile.
- NanoViricides' NV-387 could significantly improve global health by offering a safer, more effective treatment against MPox and other viral infections.
- Discover how NanoViricides' innovative NV-387, mimicking human cells, could revolutionize antiviral treatment beyond current options with limited efficacy or adverse effects.
Impact - Why it Matters
The development of NV-387 by NanoViricides represents a significant step forward in the fight against viral infections like MPox, which remains a global health concern. With its unique mechanism of action and potential to overcome the limitations of current treatments, NV-387 could offer a more effective and safer alternative. This advancement is particularly relevant in the context of increasing viral threats and the need for broad-spectrum antivirals that can be rapidly deployed in public health emergencies. The success of NV-387 could not only save lives but also reduce the economic and social impact of viral outbreaks.
Summary
NanoViricides, Inc. (NYSE American: NNVC), a leader in nanomedicine, has announced its readiness to combat the global MPox threat, leveraging its broad-spectrum antiviral NV-387. Following the WHO's extension of the Public Health Emergency of International Concern (PHEIC), the company highlighted NV-387's potential, which has successfully completed Phase I trials with a promising safety profile and is now moving towards Phase II trials in Africa. This innovative treatment mimics human cell structures to prevent viral entry, offering a potential advantage over existing treatments like tecovirimat and brincidofovir, which have shown limited effectiveness or adverse effects. NanoViricides views the upcoming trials as a critical milestone towards tapping into lucrative markets, including government bioterrorism stockpiles. For more details, visit the full press release.
NanoViricides is at the forefront of developing nanoviricide(TM) technology for antiviral therapy, with NV-387 being its lead candidate for treating a range of viral infections, including RSV, COVID-19, and MPOX/Smallpox. The company's collaboration with TheraCour Pharma, Inc. underpins its innovative approach to tackling viral diseases. For further information about NanoViricides and its groundbreaking work, visit www.NanoViricides.com.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, NanoViricides Advances NV-387 Against MPox Following WHO Alert
